Surmodics Announces Early Results from PROWL Registry Study of Real-World Limb Ischemia Patients Treated with Pounce™ Thrombectomy System
Surmodics, Inc. (SRDX)
Last surmodics, inc. earnings: 4/29 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
surmodics.gcs-web.com/investor-overview
Company Research
Source: Business Wire
Early subset analysis of 60 patients with acute, subacute, or chronic symptoms of limb ischemia demonstrated 96.8% procedural flow restoration, with 81.7% of subjects not receiving additional thromboemboli removal treatment post Pounce™ System use. EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that early results of a subset of 60 real-world acute, subacute, and chronic limb ischemia patients from its PROWL registry study were presented by Dr. Dean Ferrera at the 36th Annual TCT Symposium in Washington, D.C.PROWL is an open-label, retrospective, multi-center, U.S. registry of the Surmodics Pounce™ Thrombectomy Platform for the non-surgical removal of emboli and thrombi in the peripheral arterial vasculature. The registry is collecting real-world efficacy and safety outcomes data for endovascular interventions using the fully mechanical, non-a
Show less
Read more
Impact Snapshot
Event Time:
SRDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SRDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SRDX alerts
High impacting Surmodics, Inc. news events
Weekly update
A roundup of the hottest topics
SRDX
News
- Surmodics, Inc. (NASDAQ: SRDX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- SurModics (SRDX) is an Incredible Growth Stock: 3 Reasons Why [Yahoo! Finance]Yahoo! Finance
- Surmodics Q4 Earnings and Revenues Beat Estimates, Margin Down [Yahoo! Finance]Yahoo! Finance
- Surmodics, Inc. (NASDAQ: SRDX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.MarketBeat
- Surmodics, Inc. (NASDAQ: SRDX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
SRDX
Earnings
- 5/1/24 - Beat
SRDX
Sec Filings
- 11/15/24 - Form SCHEDULE
- 11/14/24 - Form SC
- 11/6/24 - Form SC
- SRDX's page on the SEC website